Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIGHT: Pembrolizumab and Radiotherapy for Bladder Preservation in MIBC
NCT07061964Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in muscle-invasive bladder cancer (MIBC), sponsored by National Cancer Institute. Primary endpoint: Bladder Intact Event-Free Survival at 3 years. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07061964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061964.